Process for the stereoselective preparation of bicyclic heterocycles
    3.
    发明授权
    Process for the stereoselective preparation of bicyclic heterocycles 有权
    双环杂环立体选择性制备方法

    公开(公告)号:US08263768B2

    公开(公告)日:2012-09-11

    申请号:US13057871

    申请日:2009-07-23

    IPC分类号: C07D239/72 C07D241/00

    CPC分类号: C07D241/08 C07D471/20

    摘要: The present invention relates to a process for the stereoselective preparation of compounds of general formula (I) and the salts thereof, particularly the physiologically acceptable salts thereof with inorganic or organic acids and bases, which have valuable pharmacological properties, particularly an inhibitory effect on signal transduction mediated by tyrosine kinases, the use thereof for the treatment of diseases, particularly tumoral diseases as well as benign prostatic hyperplasia (BPH), diseases of the lungs and airways.

    摘要翻译: 本发明涉及具有有价值的药理学特性,特别是对信号的抑制作用的通式(I)化合物及其盐特别是其生理上可接受的盐与无机或有机酸和碱的立体选择性制备方法。 由酪氨酸激酶介导的转导,其用于治疗疾病,特别是肿瘤疾病以及良性前列腺增生(BPH),肺和气道疾病的用途。

    PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS
    4.
    发明申请
    PROCESS FOR PREPARING CYCLOALKYL-SUBSTITUTED PIPERAZINE COMPOUNDS 审中-公开
    制备环丙基取代的哌嗪化合物的方法

    公开(公告)号:US20110301350A1

    公开(公告)日:2011-12-08

    申请号:US13058658

    申请日:2009-02-13

    IPC分类号: C07D295/135 C07D295/155

    CPC分类号: C07D295/14

    摘要: The present invention relates to a process for preparing compounds of general formula I wherein m, n, o, R1, R2 and R3 are defined as mentioned hereinafter, the enantiomers thereof and the diastereomers thereof, which are particularly suitable for preparing compounds of general formula II wherein m, o, R1, R2, R3 and R4 are defined as mentioned hereinafter. The compounds of general formula II have B1-antagonistic properties.

    摘要翻译: 本发明涉及一种制备通式I化合物的方法,其中m,n,o,R 1,R 2和R 3如下文所定义,其对映体和非对映体特别适用于制备通式 其中m,o,R 1,R 2,R 3和R 4如下文所述定义。 通式II的化合物具有B1拮抗性质。

    Novel crystalline anhydrate with anticholinergic efficacy
    10.
    发明申请
    Novel crystalline anhydrate with anticholinergic efficacy 有权
    具有抗胆碱能功效的新型结晶无水物

    公开(公告)号:US20050143410A1

    公开(公告)日:2005-06-30

    申请号:US10976624

    申请日:2004-10-29

    CPC分类号: C07D451/10

    摘要: The invention relates to a new crystalline anhydrate of tiotropium bromide, processes for preparing it and its use for preparing a pharmaceutical composition for the treatment of respiratory complaints, particularly for the treatment of COPD (chronic obstructive pulmonary disease) and asthma.

    摘要翻译: 本发明涉及噻托溴铵的新型结晶无水物,其制备方法及其用于制备用于治疗呼吸道疾病,特别是用于治疗COPD(慢性阻塞性肺疾病)和哮喘的药物组合物的用途。